Candel Therapeutics shares are trading higher after the FDA granted Orphan Drug Designation to CAN-3110.
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics shares are trading higher after the FDA granted Orphan Drug Designation to CAN-3110.

May 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics shares are trading higher after the FDA granted Orphan Drug Designation to CAN-3110.
The FDA's Orphan Drug Designation is a significant regulatory milestone that often leads to increased investor confidence and higher stock prices. This designation can provide benefits such as market exclusivity, tax credits, and reduced regulatory fees, which are likely to positively impact Candel Therapeutics' stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100